Bleeding Pattern Study

Oral Contraceptive Clinical Trial

Official title:
Comparative, Prospective, Multi-Center, Open, Randomized Study to Investigate Bleeding Patterns, Metabolic Effects, Contraceptive Efficacy, Acceptance, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 2 mg Dienogest, in Two Different Regimens of Intake (Four Extended Cycles of 84 Days Each Versus the Conventional Regimen of 21 Days) in Healthy Volunteers

Status Completed

Clinical Trial Summary

The aim of this study is to evaluate bleeding pattern, cycle control, contraceptive efficacy and safety of this oral contraceptive in two different regimens of intake.

Clinical Trial Description

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Oral Contraceptive

Clinical Trial Details

NCT number	NCT00302666
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 3
Start date	June 2003
Completion date	February 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01388491` - A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women	Phase 2
Completed	`NCT01252186` - A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women	Phase 2
Not yet recruiting	`NCT06426459` - Social Media Usage in Adolescent Girls
Recruiting	`NCT02398903` - Evaluation of Hormonal Contraceptive Treatments in Obese Women
Completed	`NCT00739622` - TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.	Phase 1
Completed	`NCT01291004` - A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives	Phase 1
Recruiting	`NCT01318005` - Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation	N/A
Recruiting	`NCT02021097` - Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception	Phase 3
Completed	`NCT00778609` - Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache	Phase 3
Completed	`NCT00972439` - Oral Contraceptive (OC) Progestin Dose and Breast Proliferation	N/A
Completed	`NCT01076582` - Comparative Trial in Hormone Withdrawal Associated Symptoms	Phase 3
Completed	`NCT00471991` - Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition	Phase 2
Completed	`NCT00248963` - Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception	Phase 3